|
|
Article: Increased OGD Funding, Not User Fees, Will Benefit Consumers, Says GPhA.
- Article from:
- PR Newswire
- Article date:
- February 17, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BOCA RATON, Fla., Feb. 17 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) today said providing a minimal amount of additional funding for the Office of Generic Drugs (OGD) will provide a tremendous return on investment, resulting in long-lasting dividends to all health care purchasers and health care programs.
"A modest investment in OGD -- such as $15 million -- would help to make more affordable medicines available to consumers and public and private health care purchasers, who would save billions of dollars," said GPhA President and CEO Kathleen Jaeger. "Those savings also would enable the administration to reach more Americans through its ...